Piramal Pharma Limited (NSE:PPLPHARMA)

Market Cap	236.99B
Revenue (ttm)	89.36B
Net Income (ttm)	-237.40M
Shares Out	1.33B
EPS (ttm)	-0.18
PE Ratio	n/a
Forward PE	100.46
Dividend	0.14 (0.08%)
Ex-Dividend Date	Jul 16, 2025

Volume	5,010,842
Average Volume	3,207,557
Open	179.20
Previous Close	178.48
Day's Range	177.98 - 182.93
52-Week Range	165.12 - 262.70
Beta	0.11
RSI	52.07
Earnings Date	Feb 4, 2026

About Piramal Pharma

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, inje...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2020
• Employees: 5,476
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: PPLPHARMA

Financial Performance

In 2024, Piramal Pharma's revenue was 91.51 billion, an increase of 11.99% compared to the previous year's 81.71 billion. Earnings were 911.30 million, an increase of 411.39%.